Loading...
•
Jun 30, 2020
Jaguar Health Q2 2020 Earnings Report
Reported consolidated financial results, with Mytesi net product revenue reaching approximately $3.2 million and gross sales approximately $6.3 million.
Key Takeaways
Jaguar Health reported its Q2 2020 financial results, featuring a significant increase in Mytesi net product revenue to $3.2 million, up from $1.7 million in Q2 2019. The company experienced a reduced net loss of $9.2 million compared to $16.7 million in the same quarter last year, driven by increased Mytesi list price and decreased operating expenses.
Mytesi net product revenue increased to approximately $3.2 million, a rise of 85.6% compared to Q2 2019.
Gross sales for Mytesi reached approximately $6.3 million, representing a 268% increase over the same period last year.
The company's net loss decreased to $9.2 million, a 45% improvement from the $16.7 million loss in Q2 2019.
Operating expenses decreased by 6% year over year, primarily due to a reduction in impairment charges and cost of product revenue.
Forward Guidance
The company is planning to host a virtual “Diarrhea Dialogues” disease education event on Tuesday, October 20, 2020.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...